# Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

> **NCT01014208** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 447 (actual)

## Conditions studied

- Lymphoma, Large-Cell, Diffuse

## Interventions

- **DRUG:** OFATUMUMAB + DHAP
- **DRUG:** RITUXIMAB + DHAP

## Key facts

- **NCT ID:** NCT01014208
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-02
- **Final completion:** 2014-11
- **Target enrollment:** 447 (ACTUAL)
- **Last updated:** 2015-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01014208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01014208, "Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01014208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*